Skip to main content
Equibles

ROVI · LABORATORIOS FARMACEUTICOS ROVI S.A · Financials

Use ROVI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ROVI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
58.1500 EUR +1.1000 (+1.93%) At close · Oct 6
Rebalance outlook locked
Market Cap
3.03B EUR
Shares
51.14M

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →

Browse captured authority reports and their original financial labels

Revenue
743.48M -2.7%
FY2025 Revenue FY2020–FY2025
Net Income
140.44M +2.6%
FY2025 Net Income FY2020–FY2025
Operating Margin
24.99% +1.5pp
FY2025 Operating Margin FY2020–FY2025
Operating Cash Flow
187.08M +35.3%
FY2025 Operating Cash Flow FY2020–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
EUR 743.48M 763.75M 829.51M 817.7M 648.68M 419.96M
EUR 30.37M 28.02M 24.33M 22.87M 21.36M 19.59M
EUR 185.78M 179.55M 220.25M 255.85M 181.39M 74.68M
EUR 2.85M 2.35M 948K 849K 905K 1.07M
EUR 183.26M 177.69M 220.41M 257.97M 182.63M 72.58M
EUR 42.9M 40.81M 50.11M 58.3M 29.55M 11.52M
EUR 140.44M 136.88M 170.34M 199.67M 153.08M 61.06M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2020–FY2025: 571.52M in buybacks, 255.17M in dividends.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current borrowings, including current portion of noncurrent borrowings 2025-12-31 EUR 28,617,000 ESEF Annual Report filed 2026-02-25
Noncurrent long-term borrowings 2025-12-31 EUR 93,204,000 ESEF Annual Report filed 2026-02-25
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.